This study was conducted on 18 insomniac patients who had vjsited neuro-psychiatric department of Eulji General Hospital from September 1, 1984 to December 31􀃸1984. The subjects were 11 males and 7 females with a mean age of 37.9 years. All had a diagnosis of primary insomnia. Patients with other psychiatric disorders or organic diseases were eliminated. Each patient was first studied for two to three preliminary baseline nights prior to the main study, and then for four to six complete main study nights. The drug and placebo nights were randomly distributed for each patients. 30 minutes before retiring to bed on a study night, each patient received 2gm of L-tryptophan with lOOmg of nicotinamid e ,10mg of pyridoxine and 500mg of ascorbic acid at drug nights or same amount of placebo at placebo nights. Sleep was investigated by means of behavioral observations every 15 minutes throughout the night and by a brief interview and questionnaire the morning after each study night. All data analyses were done separately for the entire group of 18 patients and also for this group of 14 “objectively insomniac” patients. Results of the objective observations were tabulated and analyzed for three variables. The result indicate that 2gm of L-tryptophan had a significant effect in the direction of better sleep on total sleep and sleep latency but no significant effect on number of awakenings. Overall, the results were somewhat more marked in the 14 “objectively insomniac” group than in entire sample of 18 patients. Data from questionnaires given in the morning after sleep study nights indicate that tryptophan nights were rated significantly higher than both baseline nights and placebo nights on subjective estimate of sleep but the difference between tryp-tophan and placebo did not reach statistical signi ficance and tryptophan nights were rated signific- antly higher than only baseline nights on subjective estimate of feeling state in the morning,
서 론
조사 대상 및 방법
결 과
고 안
결 론
REFERENCES